Expert Insights - 19th Annual International Ultmann Chicago Lymphoma Symposium

An on-demand 30-minute discussion between three symposium co-chairs to highlight and summarize the most clinically relevant data from the International Ultmann Chicago Lymphoma Symposium (IUCLS), an annual conference dedicated solely to the science and clinical care of lymphoma. It was organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
 
We were fortunate to have a multitude of the world’s experts in lymphoma speak at this year’s conference. The live audience was comprised of regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that included five academic centers.
 
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. This year’s conference was a 2-day live meeting to discuss recent updates in the care of patients with solid and hematologic malignancies.
 
Educational Partner: Bio Ascend
 
Medium: Interactive Module
 
Commercial Support: Support for this activity has been provided through educational grants from AbbVie Inc., Astra Zeneca, Genentech, Genmab, Janssen LP, MorphoSys, Novartis, and Seagen.

Target Audience

This activity has been designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma;
  • Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma;
  • Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data;
  • Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL;
  • Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
For more information, please contact:
CME Coordinator Contact Name: 
Conference Secretariat
CME Coordinator Contact Email: 
Summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Activity opens: 
07/15/2022
Activity expires: 
07/15/2023
SYMPOSIUM CO-CHAIRS
  Sonali M. Smith, MD
  Elwood V. Jensen Professor of Medicine
  Chief, Section of Hematology/Oncology
  Director, Lymphoma Program
  University of Chicago
 
  Andrew M. Evens, DO, MSc
  Professor of Medicine, Rutgers Robert Wood Johnson Medical School
  Associate Director for Clinical Services, Rutger Cancer Institute of New Jersey
  Director, Lymphoma Program, Division of Blood Disorders
  Medical Director, Oncology Service Line, RWJBarnabas Health
 
  Timothy S. Fenske, MD
  Professor, Division of Hematology and Oncology
  Medical College of Wisconsin
  Milwaukee, Wisconsin

 

Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
The University of Chicago Pritzker School of Medicine designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Other Healthcare Professions Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
 
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
REGISTRATION: For additional information, click the button below or visit the activity page!
 
Please login or create an account to proceed.